BioSpace News Archive

The New Jersey Housing and Mortgage Finance Agency Board today unanimously approved a $12 million investment in a new partnership with the New Jersey Hospital Association and its members to develop supportive housing as a pathway to healthier communities.

GenomeDx Biosciences, a leader in the field of urologic cancer genomics, today announced that Noridian GBA, a Medicare Administrative Contractor (MAC), has issued a draft local coverage determination (LCD) for use of the Decipher® Prostate Biopsy genomic classifier in patients with very low and low NCCN (National Comprehensive Cancer Network) risk prostate cancer.

Pursuit Vascular, Inc., manufacturer of ClearGuard® HD Antimicrobial Barrier Caps, the leading antimicrobial device for catheter-based dialysis patients, today announced that Greg Walpole has joined the company as vice president of sales.

In-Shape Health Clubs, California’s top destination for fitness and recreation, today announced its goal to raise $150,000 for cancer research in the month of October for its 4th annual Fight Cancer campaign.

Hundreds of Independent Peer-Reviewed Studies Show Positive Correlation Between RF Microwave Radiation Exposure and Biological Damage

Baxter International Inc. will host a conference call to discuss its third quarter 2018 financial results on Wednesday, October 31, 2018, at 7:30 a.m. Central Time.

Power Rogers & Smith attorneys Todd A. Smith and Brian LaCien are representing Willowbrook families who filed a class action lawsuit against Sterigenics International LLC and GTCR LLC

Acquisition to Accelerate Medtronic’s Strategy to Transform Spinal Procedures and Improve Outcomes Through Fully-Integrated Surgical Solutions

Innovent Biologics, Inc. (Innovent), a world-class China-based biopharmaceutical company that develops and commercializes high quality drugs, today presented clinical trial data from a phase Ib clinical trial (NCT02937116) that treated patients with neuroendocrine tumors

As previously announced, ISR has a Phase IIa study of HIV-infected patients on anti-retroviral therapy (ART), where patients will be randomized to receive GnRH agonist (ISR048) in addition to ART, or ART alone. The first patient is now enrolled.